Transactivation activity of human papillomavirus type 16 E6*I on aldo-keto reductase genes enhances chemoresistance in cervical cancer cells

Journal of General Virology

Volumn 93, Issue 5, 2012, Pages 1081-1092

  Wanichwatanadecha, Panata ^a   Sirsisrimangkorn, Sasinan ^a   Kaewprag, Jittranan ^a   Ponglikitmongkol, Mathurose ^a  

^a Mahidol University ^*  (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ETOPOSIDE; ONCOPROTEIN; VIRUS PROTEIN;

AKR1C1 GENE; AKR1C3 GENE; ARTICLE; CANCER CELL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SITE DIRECTED MUTAGENESIS; THERAPY RESISTANCE; TRANSACTIVATION; UTERINE CERVIX CANCER;

20-HYDROXYSTEROID DEHYDROGENASES; 3-HYDROXYSTEROID DEHYDROGENASES; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG TOLERANCE; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HOST-PATHOGEN INTERACTIONS; HUMAN PAPILLOMAVIRUS 16; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; MUTAGENESIS, SITE-DIRECTED; MUTANT PROTEINS; ONCOGENE PROTEINS, VIRAL; REPRESSOR PROTEINS; TRANSCRIPTIONAL ACTIVATION;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRIDAE;

EID: 84859851683     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.038265-0     Document Type: Article

References (52)

1. Badaracco, G., Savarese, A., Micheli, A., Rizzo, C., Paolini, F., Carosi, M., Cutillo, G., Vizza, E., Arcangeli, G. & Venuti, A. (2010). Persistence of HPV after radio-chemotherapy in locally advanced cervical cancer. Oncol Rep 23, 1093-1099.
2. Borbély, A. A., Murvai, M., Kó nya, J., Beck, Z., Gergely, L., Li, F. & Veress, G. (2006). Effects of human papillomavirus type 16 oncoproteins on survivin gene expression. J Gen Virol 87, 287-294.
3. Chen, J., Adikari, M., Pallai, R., Parekh, H. K. & Simpkins, H. (2008). Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 61, 979-987.
4. Chen, J., Emara, N., Solomides, C., Parekh, H. & Simpkins, H. (2010). Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol 66, 1103-1111.
5. Chien, C.-W., Ho, I.-C. & Lee, T.-C. (2009). Induction of neoplastic transformation by ectopic expression of human aldo-keto reductase 1C isoforms in NIH3T3 cells. Carcinogenesis 30, 1813-1820.
6. Cricca, M., Venturoli, S., Leo, E., Costa, S., Musiani, M. & Zerbini, M. (2009). Molecular analysis of HPV 16 E6I/E6II spliced mRNAs and correlation with the viral physical state and the grade of the cervical lesion. J Med Virol 81, 1276-1282.
7. de la Cruz-Hernández, E., García-Carrancá, A., Mohar-Betancourt, A., Dueñas-González, A., Contreras-Paredes, A., Pérez-Cardenas, E., Herrera-Goepfert, R. & Lizano-Soberón, M. (2005). Differential splicing of E6 within human papillomavirus type 18 variants and functional consequences. J Gen Virol 86, 2459-2468.
8. Deng, H. B., Adikari, M., Parekh, H. K. & Simpkins, H. (2004). Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol 54, 301-307.
9. Dey, A., Atcha, I. A. & Bagchi, S. (1997). HPV16 E6 oncoprotein stimulates the transforming growth factor-b1 promoter in fibroblasts through a specific GC-rich sequence. Virology 228, 190-199.
10. Filippova, M., Johnson, M. M., Bautista, M., Filippov, V., Fodor, N., Tungteakkhun, S. S., Williams, K. & Duerksen-Hughes, P. J. (2007). The large and small isoforms of human papillomavirus type 16 E6 bind to and differentially affect procaspase 8 stability and activity. J Virol 81, 4116-4129.
11. Gewin, L. & Galloway, D. A. (2001). E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J Virol 75, 7198-7201.
12. Gewin, L., Myers, H., Kiyono, T. & Galloway, D. A. (2004). Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes Dev 18, 2269-2282.
13. Hasan, U. A., Bates, E., Takeshita, F., Biliato, A., Accardi, R., Bouvard, V., Mansour, M., Vincent, I., Gissmann, L. & other authors (2007). TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J Immunol 178, 3186-3197.
14. Howie, H. L., Katzenellenbogen, R. A. & Galloway, D. A. (2009). Papillomavirus E6 proteins. Virology 384, 324-334.
15. Hsu, N.-Y., Ho, H.-C., Chow, K.-C., Lin, T.-Y., Shih, C.-S., Wang, L.-S. & Tsai, C.-M. (2001). Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 61, 2727-2731.
16. Huertas-Salgado, A., Martín-Gámez, D. C., Moreno, P., Murillo, R., Bravo, M. M., Villa, L. & Molano, M. (2011). E6 molecular variants of human papillomavirus (HPV) type 16: an updated and unified criterion for clustering and nomenclature. Virology 410, 201-215.
17. Ji, Q., Aoyama, C., Nien, Y.-D., Liu, P. I., Chen, P. K., Chang, L., Stanczyk, F. Z. & Stolz, A. (2004). Selective loss of AKR1C1 and AKR1C2 in breast cancer and their potential effect on progesterone signaling. Cancer Res 64, 7610-7617.
18. Ji, Q., Chang, L., Stanczyk, F. Z., Ookhtens, M., Sherrod, A. & Stolz, A. (2007). Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 67, 1361-1369.
19. Kösel, S., Burggraf, S., Engelhardt, W. & Olgemö ller, B. (2007). Increased levels of HPV16 E6*I transcripts in high-grade cervical cytology and histology (CIN II+) detected by rapid real-time RTPCR amplification. Cytopathology 18, 290-299.
20. Kumar, A., Zhao, Y., Meng, G., Zeng, M., Srinivasan, S., Delmolino, L. M., Gao, Q., Dimri, G., Weber, G. F. & other authors (2002). Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol 22, 5801-5812.
21. Laochariyakul, P., Ponglikitmongkol, M. & Mankhetkorn, S. (2003). Functional study of intracellular P-gp- and MRP1-mediated pumping of free cytosolic pirarubicin into acidic organelles in intrinsic resistant SiHa cells. Can J Physiol Pharmacol 81, 790-799.
22. Liu, Y., Chen, J. J., Gao, Q., Dalal, S., Hong, Y., Mansur, C. P., Band, V. & Androphy, E. J. (1999). Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 73, 7297-7307.
23. Liu, X., Yuan, H., Fu, B., Disbrow, G. L., Apolinario, T., Tomaic, V., Kelley, M. L., Baker, C. C., Huibregtse, J. & Schlegel, R. (2005). The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein. J Biol Chem 280, 10807-10816.
24. López-Ocejo, O., Viloria-Petit, A., Bequet-Romero, M., Mukhopadhyay, D., Rak, J. & Kerbel, R. S. (2000). Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 19, 4611-4620.
25. Münger, K., Phelps, W. C., Bubb, V., Howley, P. M. & Schlegel, R. (1989). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 63, 4417-4421.
26. Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J., Meijer, C. J. &International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348, 518-527.
27. Nees, M., Geoghegan, J. M., Hyman, T., Frank, S., Miller, L. & Woodworth, C. D. (2001). Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kB-responsive genes in cervical keratinocytes. J Virol 75, 4283-4296.
28. Oh, S. T., Kyo, S. & Laimins, L. A. (2001). Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J Virol 75, 5559-5566.
29. Pallai, R., Simpkins, H., Chen, J. & Parekh, H. K. (2010). The CCAAT box binding transcription factor, nuclear factor-Y (NF-Y) regulates transcription of human aldo-keto reductase 1C1 (AKR1C1) gene. Gene 459, 11-23.
30. Penning, T. M., Burczynski, M. E., Jez, J. M., Hung, C.-F., Lin, H.-K., Ma, H., Moore, M., Palackal, N. & Ratnam, K. (2000). Human 3ahydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351, 67-77.
31. Penning, T.M., Jin, Y., Steckelbroeck, S., Lanisnik Rizner, T. & Lewis, M. (2004). Structure-function of human 3a-hydroxysteroid dehydrogenases: genes and proteins. Mol Cell Endocrinol 215, 63-72.
32. Peralta-Zaragoza, O., Bermúdez-Morales, V., Gutiérrez-Xicotencatl, L., Alcocer-González, J., Recillas-Targa, F. & Madrid-Marina, V. (2006). E6 and E7 oncoproteins from human papillomavirus type 16 induce activation of human transforming growth factor b1 promoter throughout Sp1 recognition sequence. Viral Immunol 19, 468-480.
33. Pim, D. & Banks, L. (1999). HPV-18 E6*I protein modulates the E6- directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene 18, 7403-7408.
34. Pim, D., Massimi, P. & Banks, L. (1997). Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene 15, 257-264.
35. Pim, D., Tomaic, V. & Banks, L. (2009). The human papillomavirus (HPV) E6* proteins from high-risk, mucosal HPVs can direct degradation of cellular proteins in the absence of full-length E6 protein. J Virol 83, 9863-9874.
36. Rampias, T., Sasaki, C., Weinberger, P. & Psyrri, A. (2009). E6 and E7 gene silencing and transformed phenotype of human papillomavirus 16-positive oropharyngeal cancer cells. J Natl Cancer Inst 101, 412-423.
37. Rižner, T. L., Śmuc, T., Rupreht, R., Śinkovec, J. & Penning, T. M. (2006). AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 248, 126-135.
38. Schmittgen, T. D. & Livak, K. J. (2008). Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3, 1101-1108.
39. Sedman, S. A., Barbosa, M. S., Vass, W. C., Hubbert, N. L., Haas, J. A., Lowy, D. R. & Schiller, J. T. (1991). The full-length E6 protein of human papillomavirus type 16 has transforming and trans-activating activities and cooperates with E7 to immortalize keratinocytes in culture. J Virol 65, 4860-4866.
40. Selga, E., Noé, V. & Ciudad, C. J. (2008). Transcriptional regulation of aldo-keto reductase 1C1 in HT29 human colon cancer cells resistant to methotrexate: role in the cell cycle and apoptosis. Biochem Pharmacol 75, 414-426.
41. Shally, M., Alloul, N., Jackman, A., Muller, M., Gissmann, L. & Sherman, L. (1996). The E6 variant proteins E6I-E6IV of human papillomavirus 16: expression in cell free systems and bacteria and study of their interaction with p53. Virus Res 42, 81-96.
42. Shirasawa, H., Jin, M. H., Shimizu, K., Akutsu, N., Shino, Y. & Simizu, B. (1994). Transcription-modulatory activity of full-length E6 and E6*I proteins of human papillomavirus type 16. Virology 203, 36-42.
43. Śmuc, T. & Rizner, T. L. (2009). Expression of 17b-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines. Chem Biol Interact 178, 228-233.
44. Stacey, S. N., Jordan, D., Snijders, P. J., Mackett, M., Walboomers, J. M. & Arrand, J. R. (1995). Translation of the human papillomavirus type 16 E7 oncoprotein from bicistronic mRNA is independent of splicing events within the E6 open reading frame. J Virol 69, 7023-7031.
45. Storrs, C. H. & Silverstein, S. J. (2007). PATJ, a tight junctionassociated PDZ protein, is a novel degradation target of high-risk human papillomavirus E6 and the alternatively spliced isoform 18 E6. J Virol 81, 4080-4090.
46. Tao, M., Kruhlak, M., Xia, S., Androphy, E. & Zheng, Z. M. (2003). Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells. J Virol 77, 13232-13247.
47. Tungteakkhun, S. S., Filippova, M., Fodor, N. & Duerksen-Hughes, P. J. (2010). The full-length isoform of human papillomavirus 16 E6 and its splice variant E6* bind to different sites on the procaspase 8 death effector domain. J Virol 84, 1453-1463.
48. Ueda, M., Hung, Y.-C., Chen, J.-T., Chiou, S.-H., Huang, H.-H., Lin, T.-Y., Terai, Y. & Chow, K.-C. (2006). Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol Oncol 102, 173-181.
49. Vaeteewoottacharn, K., Chamutpong, S., Ponglikitmongkol, M. & Angeletti, P. C. (2005). Differential localization of HPV16 E6 splice products with E6-associated protein. Virol J 2, 50.
50. Wang, J., Shou, J. & Chen, X. (2000). Dickkopf-1, an inhibitor of the Wnt signaling pathway, is induced by p53. Oncogene 19, 1843-1848.
51. Wang, H.-W., Lin, C.-P., Chiu, J. -H., Chow, K.-C., Kuo, K.-T., Lin, C.-S. & Wang, L.-S. (2007). Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer 120, 2019-2027.
52. Zupanska, A. & Kaminska, B. (2002). The diversity of p53 mutations among human brain tumors and their functional consequences. Neurochem Int 40, 637-645.